Retrospective evaluation of a TEN/SJS series managed with a new treatment protocol

Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, life-threatening diseases without standardized treatment. The mortality rate ranges from 20% to 50%, and can reach up to 90%, based on the severity index SCORTEN. Albeit critical, no active systemic therapeutic regimen with unequivocal benefit exists as of yet; most included cyclosporine A (CyA), immunoglobulins (IVIG) or systemic glucocorticosteroids (GCS). Anti-TNF therapy has been described as beneficial in some reports, and a randomized controlled trial was discontinued prematurely because of death excess in the thalidomide treatment group. In the EuroSCAR cohort study, administration of IVIG resulted in a mortality rate of 34% (IVIG alone) and 18% (IVIG and corticosteroids).

Other Information

Published in: Journal of the European Academy of Dermatology and Venereology
License: http://creativecommons.org/licenses/by-nc-nd/4.0/
See article on publisher's website: https://dx.doi.org/10.1111/jdv.20060